대한불안의학회지 (Anxiety and mood)

  • 제20권2호
  • /
  • Pages.54-64
  • /
  • 2024
  • /
  • 2586-0151(pISSN)
  • /
  • 2586-0046(eISSN)
대한불안의학회 (Korean Academy of Anxiety Disorders)
권호 표지
DOI QR코드

DOI QR Code

2024 한국형 범불안장애 치료지침: 초기 및 유지 약물치료 전략

Korean Guidelines for the Treatment of Generalized Anxiety Disorder 2024: Initial and Maintenance Treatment Strategies for the Pharmacological Treatment of Generalized Anxiety Disorder

  • 김민경 (차의과학대학교 정신건강의학교실) ;
  • 서준호 (연세대학교 원주의과대학 정신건강의학교실) ;
  • 박천일 (연세대학교 의과대학 정신과학교실) ;
  • 안명희 (서울아산병원 건강의학과) ;
  • 이현아 (순천향대학교 의과대학 정신건강의학교실) ;
  • 장윤영 (인제대학교 의과대학 정신건강의학교실) ;
  • 문은수 (부산대학교 의과대학 정신건강의학교실) ;
  • 서호석 (서호석연세정신건강의학과) ;
  • 김원 (인제대학교 의과대학 정신건강의학교실) ;
  • 이경욱 (가톨릭대학교 의과대학 정신건강의학교실)
  • Min-Kyoung Kim (Department of Psychiatry, CHA Ilsan Medical Center, CHA University) ;
  • Jun Ho Seo (Department of Psychiatry, Yonsei University Wonju College of Medicine) ;
  • Chun Il Park (Department of Psychiatry, Yonsei University College of Medicine) ;
  • Myung Hee Ahn (Division of Psychiatry, Health Screening and Promotion Center, Asan Medical Center) ;
  • Hyeon-Ah Lee (Department of Psychiatry, College of Medicine, Soonchunhyang University Cheonan Hospital) ;
  • Yoon Young Chang (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Eunsoo Moon (Department of Psychiatry, Pusan National University School of Medicine) ;
  • Ho-Suk Suh (Suh Hosuk Yonsei Psychiatry Clinic for Healthy Mind) ;
  • Won Kim (Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Kyoung-Uk Lee (Department of Psychiatry, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, College of Medicine)
  • 투고 : 2024.10.21
  • 심사 : 2024.10.29
  • 발행 : 2024.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective : The Korean Association of Anxiety Disorders developed Korean guidelines for the treatment of generalized anxiety disorder (GAD) 2024. In this paper, we discussed the consensus among psychiatrists specializing in anxiety disorders, regarding initial and maintenance treatment strategies for pharmacological treatment of GAD in Korea. Methods : The executive committee developed questionnaires on treatment strategies for patients with GAD, based on previous treatment guidelines and academic articles published internationally and in Korea. Sixty-two experts responded to the questionnaires. The consensus of expert opinions was classified into three categories (first-line, second-line, and third-line choices) using the chi-square test and 95% confidence intervals. Results : Combination of antidepressants and anxiolytics was recommended as treatments of choice (ToC), and antidepressant single pharmacotherapy as first-line strategies for initial treatment of GAD. Several SSRI, SNRI, and mirtazapine were preferred from among many antidepressants, and, among anti-anxiety drugs, clonazepam, alprazolam, buspirone, and lorazepam were first preferred. In the case of maintenance treatment of GAD, antidepressant single pharmacotherapy was selected as ToC and first-line strategies. In addition, it was reported that the preference for atypical antipsychotics was high not only in the initial but also in the maintenance treatment stage as antidepressants and atypical antipsychotics combination treatment maintained the top second-line strategies. Patients were typically examined every four weeks during treatment, to review effectiveness and side effects of the drug. Pharmacotherapy was generally continued for one year or more. Conclusion : This study is based on the clinical experience of Korean experts regarding pharmacological treatment strategies for patients with GAD, and and it is expected to be helpful in presenting the basis and plan for GAD treatment in clinical practice.

키워드

참고문헌

  1. Ruscio AM, Hallion LS, Lim CCW, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, et al. Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. JAMA Psychiatry 2017;74:465-475.
  2. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162-171.
  3. Lee JY, Kim MS, Lee SH, Yang JC, Kim CH, Yu BH, et al. Korean medication algorithm project for generalized anxiety disorder 2009 (II): medication algorithm & long-term medication treatment strategy. J Korean Neuropsychiatr Assoc 2010;49:553-563.
  4. Bandelow B, Allgulander C, Baldwin DS, Costa D, Denys D, Dilbaz N, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders-Version 3. Part II: OCD and PTSD. World J Biol Psychiatry 2023;24:118-134.
  5. Buszewicz M, Cape J, Serfaty M, Shafran R, Kabir T, Tyrer P, et al. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines. Health Technol Assess 2017;21:1-138.
  6. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:S1.
  7. Zimmerman N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Med J Aust 2018;209:43.
  8. Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol 2016;31:249-258.
  9. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy 2010;30:942-951.
  10. Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-1158.
  11. Hoge EA, Worthington JJ, 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008;13:522-527.
  12. Szeleszczuk L, Fraczkowski D. Propranolol versus other selected drugs in the treatment of various types of anxiety or stress, with particular reference to stage fright and post-traumatic stress disorder. Int J Mol Sci 2022;23:17.
  13. De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon Outcomes Res 2012;4:157-168.
  14. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 2013;9:883-892.
  15. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R. Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. Clinicoecon Outcomes Res 2015;7:299-312.
  16. Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry 2022;27:1339-1349.